The DOI matches its Crossref record; 162 of the 165 references it cites were found in a registry or an index.
Association of metabolic syndrome and chronic kidney disease
Open accessAbstract
The prevalence of kidney disease is increasing rapidly worldwide, reflecting rising rates of obesity, diabetes, and associated metabolic syndrome (MetS). Chronic kidney disease and related comorbidities such as obesity, diabetes, and hypertension place a significant financial burden on healthcare systems. Despite the widespread use of RAAS inhibitors, intensive blood pressure and glycemic control, and newer therapeutic options consisting of sodium/glucose cotransporter-2 (SGLT-2) inhibitors or glucagon-like peptide-1 (GLP-1) receptor agonists, a significant risk of progression to end-stage renal disease remains in the high-risk obese and diabetic population. The MetS is a cluster of cardiovascular risk factors that adversely affect the development and progression of chronic kidney failure. According to the criteria of the World Health Organization, it is defined by visceral adiposity, impaired glucose tolerance or insulin resistance, atherogenic dyslipidemia, raised blood pressure, and microalbuminuria with a albumin-to-creatinine ratio ≥30 mg/g. At molecular level MetS is marked by a proinflammatory state and increased oxidative stress leading to various pathophysiological changes causing endothelial dysfunction and a hypercoagulable state. Because the kidney is a highly vascularized organ, it is especially susceptible for those microvascular changes. Therefore, the MetS and its individual components are associated with the premature development, acceleration, and progressio…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although the study was not designed to examine mechanism(s) underlying CVD risk reduction in CKM, cardioprotective properties of EPA that offset inflammation and oxidative stress while improving endothelial function may have been operative in this high-risk phenotype [[15], [16], [17], [18]].”
From Icosapent ethyl reduces CVD risk in cardiovascular-kidney-metabolic syndrome: REDUCE-IT CKM (2026) · cites this paper as [17]
Citations
Cites
Alberti, K. G. M. M., Eckel, R. H., Grundy, S. M., Zimmet, P. Z., Cleeman, J. I., Donato, K. A., Fruchart, J.-C., James, W. P. T., Loria, C. M., & Smith, S. C. (2009) · Circulation · doi:10.1161/circulationaha.109.192644 · Cited by 14,860
2018 ESC/ESH Guidelines for the management of arterial hypertension
Williams, B., Mancia, G., Spiering, W., Agabiti Rosei, E., Azizi, M., Burnier, M., Clement, D. L., Coca, A., de Simone, G., Dominiczak, A., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy339 · Cited by 10,286
The metabolic syndrome—a new worldwide definition
Alberti, K. G. M., Zimmet, P., & Shaw, J. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67402-8 · Cited by 9,352
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
Dapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618
Cardiovascular and renal outcomes with empagliflozin in heart failure
Packer, M., Anker, S. D., Butler, J., Filippatos, G., Pocock, S. J., Carson, P., Januzzi, J., Verma, S., Tsutsui, H., Brueckmann, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022190 · Cited by 5,206
Eslam, M., Newsome, P. N., Sarin, S. K., Anstee, Q. M., Targher, G., Romero-Gomez, M., Zelber-Sagi, S., Wai-Sun Wong, V., Dufour, J.-F., Schattenberg, J. M., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.03.039 · Cited by 4,472
Research works printed but not linked: 4
- World Health O, 1999, Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO consultation. Part 1, Diagnosis and classification of diabetes mellitus
- Aihara K, 2010, Transforming growth factor‐β1 as a common target molecule for development of cardiovascular diseases, renal insufficiency and metabolic syndrome, Cardiol Res Pract, 2011
- Scurt FG, 2020, Paradigm shift in understanding acute kidney injury in patients with chronic liver disease: from pathophysiology to defining disease entities, Z Gastroenterol, 58, 254
- McMurray JJV, 2020, Dapagliflozin in patients with heart failure and reduced ejection fraction, Reply N Engl J Med, 382, 973
Cited by
Sorted by citations
Items 101–161 of 161
Cai, D., Fang, J., Wei, J., Gong, C., Chen, X., Wu, Z., Yin, M., An, H., Guo, L., Lin, S., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-6935801/v1
Takahashi, T., Beppu, T., Hosoya, T., & Yokota, N. (2025) · Clinical and Experimental Nephrology · doi:10.1007/s10157-025-02750-4
Metabolic syndrome: Pharmacological strategies and challenges
Heidari, R. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-27370-4.00014-7
Esparham, A., Black, R., Khalil, M., Moghadam, H. A., Bolender, G., Kathuria, P., & Khorgami, Z. (2025) · Obesity Surgery · doi:10.1007/s11695-025-08195-8
Yerokhovych, V., Karpenko, O., Ilkiv, Y., GURIANOV, V., Krasnienkov, D. S., Sulaieva, O., Komisarenko, I., Falalyeyeva, T. M., & Kobyliak, N. M. (2025) · Minerva Biotechnology and Biomolecular Research · doi:10.23736/s2724-542x.25.03266-3
Yang, X., Li, Q., He, Y., Yin, G., Li, M., Zhu, W., Fan, X., Gong, Y., Wang, Y., Qiang, W., et al. (2025) · Clinical Epidemiology · doi:10.2147/clep.s536091
Ghaemi, F., Hedayati, F., Esteghamati, A., Peysepar, R., Deravi, N., & Meysamie, A. (2025) · BMC Endocrine Disorders · doi:10.1186/s12902-025-02050-8
Jiang, L., Chen, Y., Cong, X., Wang, H., Jiang, T., Yang, M., Xiao, B., Xiao, L., & Chen, Y. (2025) · International Journal of Endocrinology · doi:10.1155/ije/9237368
Effects of short-term very low-calorie diet on metabolic profile in patients with metabolic syndrome
Zhou, Y., Li, S., Hu, T., Hu, S., Li, N.-F., Fan, Y.-J., Yu, J.-W., Yuan, Y., Chen, Y., Sun, M.-X., et al. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1671870 · Cited by 1
Modulation of Sirtuin-1 by Resveratrol as a Potential Therapy in Alleviating Metabolic Syndrome
Ghapor, A. A. A., Nasir, N. A. A., Sadikan, M. Z., Razali, N., & Reshidan, N. H. (2025) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-025-01955-4 · Cited by 1
Shen, N., Lu, S., Kong, Z., Gao, Y., Hu, J., Si, S., Wang, J., Li, J., Han, W., Wang, R., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26750042
Shen, N., Lu, S., Kong, Z., Gao, Y., Hu, J., Si, S., Wang, J., Li, J., Han, W., Wang, R., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26750054
Shen, N., Lu, S., Kong, Z., Gao, Y., Hu, J., Si, S., Wang, J., Li, J., Han, W., Wang, R., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26750045
Shen, N., Lu, S., Kong, Z., Gao, Y., Hu, J., Si, S., Wang, J., Li, J., Han, W., Wang, R., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26750036
Shen, N., Lu, S., Kong, Z., Gao, Y., Hu, J., Si, S., Wang, J., Li, J., Han, W., Wang, R., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26750039
Shen, N., Lu, S., Kong, Z., Gao, Y., Hu, J., Si, S., Wang, J., Li, J., Han, W., Wang, R., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26750033
Shen, N., Lu, S., Kong, Z., Gao, Y., Hu, J., Si, S., Wang, J., Li, J., Han, W., Wang, R., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26750057
Wei, X., Wei, J., Feng, J., Li, C., Zhang, Z., Hu, B., Long, N., & Luo, C. (2024) · Figshare · doi:10.6084/m9.figshare.26698481
Shen, N., Lu, S., Kong, Z., Gao, Y., Hu, J., Si, S., Wang, J., Li, J., Han, W., Wang, R., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26750051
Shen, N., Lu, S., Kong, Z., Gao, Y., Hu, J., Si, S., Wang, J., Li, J., Han, W., Wang, R., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26750048
Zhao, Z., Ni, X., Xu, J., Ran, X., Wang, T., Zhang, P., Chen, Y., Ma, H., & Wu, Q. (2025) · Journal of Multidisciplinary Healthcare · doi:10.2147/jmdh.s560234
Trandafir, A. L., Colasse, O., Ghitea, M. C., Ghiţea, E. C., Ghitea, T. C., Brata, R. D., & Jurcă, A. D. (2025) · Medicina · doi:10.3390/medicina62010066
Fu, R., Wang, N., Yuan, Z., Lin, Y., He, S., Yang, Q., & Hu, Z. (2026) · International Journal of Health Geographics · doi:10.1186/s12942-025-00449-z
Yuting, T., & Hujiaaihemaiti, M. (2026) · Research Square · doi:10.21203/rs.3.rs-8346554/v1
Li, M., Zhao, H., Bai, Y., Chen, J., Chen, C. C., Qin, L., Zhu, Z., Liu, J., & Zhang, Z. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1716058
Dyslipidemia: current approaches to pharmacological and non-pharmacological management
Андреевич, Г. И., & Bakhareva, Y. S. (2026) · Ateroscleroz · doi:10.52727/2078-256x-2025-21-4-440-452
Stage-specific utility of obesity indices across the chronic kidney disease continuum
Zhu, Z., Ren, K., Duan, X., Hu, X., Lv, Y., Wang, D., Jin, H., Zhang, L., & Wang, Y. (2026) · Renal Failure · doi:10.1080/0886022x.2026.2646000
Alshahrani, S., El‐Metwally, A., Alshahrani, A. S., Al-Khateeb, B. F., Aldubikhi, A. I. S., Angawi, K., Alharthy, A., Alnaim, L., Zaidan, A. M., & Aldahash, R. (2026) · JMIR Public Health and Surveillance · doi:10.2196/81849
Abid, H., Vazaym, M., Jawad, M., Lohano, G., Shah, S. M. A., & Khan, N. A. (2026) · Research Square · doi:10.21203/rs.3.rs-8993837/v1
Yao, X., Lin, Z., Huang, X., Lin, S., & Zhang, Z. (2026) · European journal of medical research · doi:10.1186/s40001-026-04310-2
Yang, Y., Zhou, W., Yang, M., Tang, S. C. W., & Liu, B.-C. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1800868
Li, Y., & Hujiaaihemaiti, M. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1769722
Nerbass, F. B., Hanauer, M. A., da Silva, I. F., da Costa, T. F., da Silva, R. M., Fabre, L., Vieira, M. A., & Cálice-Silva, V. (2026) · Epidemiologia e Serviços de Saúde · doi:10.1590/s2237-96222026v35e20250690.pt
Nerbass, F. B., Hanauer, M. A., da Silva, I. F., da Costa, T. F., da Silva, R. M., Fabre, L., Vieira, M. A., & Cálice-Silva, V. (2026) · Epidemiologia e Serviços de Saúde · doi:10.1590/s2237-96222026v35e20250690.en
Factors associated with albuminuria in non-diabetic severe obesity
Toussaint, R., Gentes, E., Pouget, M., Farigon, N., Miolanne, M., Picard, M., Lambert, C., Heng, A.-É., & Boirie, Y. (2026) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2026.103282
Li, H., He, Y., Chen, B., Liu, Z., Zhu, Z., Zhu, W., & Chen, S. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1725996
Triglyceride–Glucose Index and Acute Kidney Injury: A Systematic Review and Meta-Analysis
Yang, Y.-W., Yu, J., Gong, L., Ge, M., & Wan, Z. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15093390
Chen, C.-C., Huang, H., Tsai, I.-N., Lee, H., & Wang, C. (2026) · Antioxidants · doi:10.3390/antiox15050636
Kim, J. G., Lee, Y. H., Chung, S., Hwang, H. S., Han, K., & Yoon, H. E. (2026) · JMIR Public Health and Surveillance · doi:10.2196/73750
Yu, Y., Shan, X., Tang, X., Ding, Y., & An, X. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1854958
The associations between cardiometabolic index and mortalities in chronic kidney disease
Li, J., & Cao, H. (2026) · Medicine · doi:10.1097/md.0000000000049696
Miri, M., Ghahfarokhi, M. K., Mohseni, S., Golestani, A., Akbarpour, S., Sani, M. P., & Tabatabaei‐Malazy, O. (2026) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70282
Lee, J.-Y., Kim, H., Yon, D. K., Lee, J. P., Rhee, S. Y., Kwon, S., Park, S., Kim, Y., & Hwang, H. S. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1866115
Medina-Santos, G., Urzúa, A., Méndez-Cornejo, J., Rojas-Mancilla, E., Zambrano-Bravo, C., Oñate-Henríquez, E., Parada, T., & Vidal-Silva, C. (2026) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph23080955 · Cited by 1
Yi, S., Qiu, W., Zhu, Y., Wu, S., Zheng, H., 黃秋錦, Feng, Y., & Wu, Y. (2026) · International Journal of Endocrinology · doi:10.1155/ije/6690501
Patterns of Antidiabetic Therapy and Associated Metabolic Profiles in Routine Clinical Practice
Moisi, M. I., Vesa, C. M., Dorobanțu, F. R., Cinezan, C., Ghitea, T. C., & Brata, R. D. (2026) · Diabetology · doi:10.3390/diabetology7080145
Wang, X., Yang, M., Ma, Q., Chang, X., Wang, G., Liu, J., & Wu, J. (2026) · International Journal of Endocrinology · doi:10.1155/ije/1409909
Tao, W., Chen, C., Zhang, J., Jiang, X., & Deng, L. (2026) · Medicine · doi:10.1097/md.0000000000050111
Association of HDL2b with chronic kidney disease in type 2 diabetes mellitus populations
Tang, H., Ye, Z., 洪国保, Li, X., 梁燕萍, Zou, H., & Deng, D. X.-F. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1868445
Mohn, A., Pietro, G. D., Maggitti, A., Trisi, G., Polidori, N., & Chiarelli, F. (2026) · Hormone Research in Paediatrics · doi:10.1159/000552607
Zhang, F., Hou, X., Tan, C., Yin, B., Bing, L., Zhong, Y., Liu, K., 廖鑫鑫, & Liu, H. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1866149
Ladeira, K. C., Bastos, A. A., Martinez, R. M., & de Paula, T. P. (2026) · Brazilian Journal of Nephrology · doi:10.1590/2175-8239-jbn-2025-0350en
Ladeira, K. C., Bastos, A. A., Martinez, R. M., & de Paula, T. P. (2026) · Brazilian Journal of Nephrology · doi:10.1590/2175-8239-jbn-2025-0350pt
Zhang, J., Li, X., Chen, C., Wu, Z., Qin, F., Li, Y., Zhang, Y., & Ning, C. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1912904
Wittke, C. I., Watt, D. M., Butler, L., Lyons, A. M., Clarke, C. J., Mullen, C., Clements, N., Lawlor, A., Athineos, D., Young, A., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.09.02.748892
Research Progress on the Correlation between CKD and CKM
戚, 玉. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.1693131
Cardiovascular–Kidney–Metabolic Syndrome and Its Hepatic Dimension: A Narrative Review
Enache, V., Popescu, D.-C., Marcu, B., Diaconu, M., & Nechita, A. C. (2026) · Medicina · doi:10.3390/medicina62091742
Kondratyuk, M. O., Radchenko, O., Korolyuk, O. Y., & Komarytsia, O. Y. (2026) · Experimental and Clinical Medicine · doi:10.35339/ekm.2026.95.1.krk
Binu, S. K., & Devi, R. (2026) · International Conference on Secure Information Systems and Technologies (ICSIST) · doi:10.1109/icsist70215.2026.11706390
Interrelationship of Tissue Factor With Thromboinflammatory Biomarkers in ESRD and CKD 5 Patients
Rohde, L., Siddiqui, F., Konczak, K. E., Kaufmann, E., Hoppensteadt, D., Walenga, J. M., Vinod, B., Hussain, H., Fareed, J., & Vellanki, K. (2026) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/10760296261496960
Myrrha, A., Vieira, D. A., Blaudt-Meira, A., Carvalho, C. C., Vizzoni, L. H., Rocha, L. A., Rivelo, I. D. S., Moreira, P. H. C., Ferreira, B. X., Chagas-Sena, M., et al. (2026) · IntechOpen eBooks · doi:10.5772/intechopen.1017915
Metadata
- Authors
- Scurt, F. G., Ganz, M. J., Herzog, C., Bose, K., Mertens, P. R., & Chatzikyrkou, C.
- Affiliations
- University Clinic for Nephrology and Hypertension, Diabetology and Endocrinology (DE)
- Klinikum Magdeburg (DE)
- Medizinische Hochschule Hannover (DE)
- Corresponding author
- Scurt, Florian G.
- Venue
- Obesity Reviews
- Publisher
- Wiley
- Published
- 2023-10-02
- Volume
- 25
- Issue
- 1
- Pages
- e13649-e13649
- ISSN
- 1467-7881 (ISSN-L)
- 1467-789X
- OpenAlex
- W4387246542
- Cited by
- 155
- References
- 165
- Citations by year
- 2026: 50 · 2025: 75 · 2024: 29 · 2023: 1
- FWCI
- 6.77
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Obesity Reviews (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- metabolic syndrome, chronic kidney disease, obesity, diabetes mellitus, insulin resistance, microalbuminuria, endothelial dysfunction, oxidative stress, inflammation, end-stage renal disease, renal hemodynamics, renal metabolism, SGLT2 inhibitors, GLP-1 receptor agonists, renin-angiotensin system inhibitors
- MeSH terms
- Diabetes Mellitus, Humans, Insulin Resistance, Obesity, Metabolic Syndrome, Renal Insufficiency, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
